BIOMIND LABS INC. (3XI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BIOMIND LABS INC. (3XI) has a cash flow conversion efficiency ratio of 0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.70K ≈ $-45.24K USD) by net assets (€-1.56 Million ≈ $-1.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 3XI equity to assets ratio to measure how much of total assets are equity-financed.
BIOMIND LABS INC. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how BIOMIND LABS INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BIOMIND LABS INC. (3XI) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
BIOMIND LABS INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BIOMIND LABS INC. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ODI PHARMA AB
F:6OD
|
N/A |
|
Axilion Smart Mobility Ltd
TA:AILN
|
-0.914x |
|
Super League Enterprise Inc.
NASDAQ:SLE
|
1.401x |
|
BPH Global Ltd
AU:BP8
|
0.413x |
|
WOODPECKER.CO ZY -10
F:8FG
|
0.072x |
|
N2OFF Inc
NASDAQ:NITO
|
-0.089x |
|
Coloseum Holding a.s.
PR:COLOS
|
N/A |
|
PBS Finanse SA
WAR:PBF
|
-0.083x |
Annual Cash Flow Conversion Efficiency for BIOMIND LABS INC. (2021–2024)
The table below shows the annual cash flow conversion efficiency of BIOMIND LABS INC. from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see 3XI market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-1.30 Million ≈ $-1.52 Million |
€-354.43K ≈ $-414.36K |
0.273x | -49.03% |
| 2023-12-31 | €-1.43 Million ≈ $-1.67 Million |
€-765.93K ≈ $-895.45K |
0.535x | -93.84% |
| 2022-12-31 | €-247.66K ≈ $-289.54K |
€-2.15 Million ≈ $-2.51 Million |
8.685x | +997.29% |
| 2021-12-31 | €2.19 Million ≈ $2.56 Million |
€-2.12 Million ≈ $-2.48 Million |
-0.968x | -- |
About BIOMIND LABS INC.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more